Right now, the Centers for Medicare and Medicaid Services (CMS) are deliberating whether or not they will offer high-risk Medicare beneficiaries access to lifesaving lung cancer screening. Despite the overwhelming evidence that lung cancer screening could save tens of thousands of lives, some maintain that Medicare coverage would simply be too costly.
But a study published just last Friday in the August issue of American Health and Drug Benefits, conducted by Milliman, Inc., helps advocates clear the final coverage hurdle, proving the cost-effectiveness of the early detection of lung cancer in high-risk Medicare beneficiaries.
Read more